NASDAQ: LIFEAtyr Pharma Inc Stock
$1.60-0.02 (-1.23%)
Updated Apr 24, 2024
LIFE Price
$1.60
Fair Value Price
$0.12
Market Cap
$108.40M
52 Week Low
$1.08
52 Week High
$2.70
P/E
-1.7x
P/B
1.2x
P/S
214.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$353.00k
Earnings
-$50.39M
Gross Margin
100%
Operating Margin
-14,274.5%
Profit Margin
-14,274.5%
Debt to Equity
0.33
Operating Cash Flow
-$33M
Beta
0.83
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LIFE Overview
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LIFE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIFE ($1.60) is overvalued by 1,283.08% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LIFE ($1.60) is not significantly undervalued (1,283.08%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LIFE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LIFE due diligence checks available for Premium users.
Be the first to know about important LIFE news, forecast changes, insider trades & much more!
LIFE News
Valuation
LIFE fair value
Fair Value of LIFE stock based on Discounted Cash Flow (DCF)
Price
$1.60
Fair Value
$0.12
Overvalued by
1,283.08%
LIFE ($1.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LIFE ($1.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LIFE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LIFE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.7x
Industry
15.69x
Market
41.27x
LIFE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.2x
Industry
5.86x
LIFE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LIFE's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.8M
Profit Margin
0%
LIFE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LIFE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$120.7M
Liabilities
$30.2M
Debt to equity
0.33
LIFE's short-term assets ($102.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIFE's short-term assets ($102.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIFE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LIFE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.1M
Investing
$17.8M
Financing
$6.0M
LIFE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LIFE vs Biotech Stocks
Atyr Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.